Get started
Author

Neha Puttagunta

Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?
2021 · Julie Joseph, Benjamin Rahmani, et al. · Journal of Neuroimmune Pharmacology · 16
PDF
Viral vs. Non-Viral Combined Hepatocellular–Cholangiocarcinoma: Distinct Genomic Landscapes and Survival Outcomes
2026 · Neha Puttagunta, Matthew Friedman, et al. · Journal of Gastrointestinal Cancer · 1
Use of intravenous immunoglobulin in combination with corticosteroids for immune checkpoint inhibitor pneumonitis
2026 · Neha Puttagunta, Saman Suleman, et al. · BMJ Case Reports · 1
993 Optimizing management of immune checkpoint inhibitor-mediated toxicity in cancer patients
2026 · Neha Puttagunta, Michael Barsoum, et al. · Journal for ImmunoTherapy of Cancer
Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts
2026 · Marisa Siebel, Meredith Akerman, et al. · Journal of Gastrointestinal Oncology
PP01.38: Genomic Landscape and Clinical Characteristics of Early-Onset Lung Cancer: An Integrative Analysis Using cBioPortal
2026 · Divya Chukkalore, Wint Yan Aung, et al. · Journal of Thoracic Oncology
Impact of first-line EGFR TKI dose reduction on survival and treatment sequencing in metastatic EGFR -mutant non–small cell lung cancer: A real-world cohort study.
2026 · Divya Chukkalore, Wint Yan Aung, et al. · Journal of Clinical Oncology
De novo vs recurrent metastatic presentation and outcomes with first-line EGFR TKI in EGFR -mutant NSCLC.
2026 · Wint Yan Aung, Divya Chukkalore, et al. · Journal of Clinical Oncology
Real-world outcomes in EGFR subtypes and co- TP53 mutations in metastatic non-small cell lung cancer.
2026 · Nina Cheranda, Neha Puttagunta, et al. · Journal of Clinical Oncology
Understanding the impact of GTF2I mutations in thymic epithelial tumors: Characteristics and clinicogenomic outcomes.
2026 · Neha Puttagunta, Nina Cheranda, et al. · Journal of Clinical Oncology
Age-vulnerability interaction and real-world treatment outcomes in EGFR -mutant non–small cell lung cancer.
2026 · Juliet Meir, Divya Chukkalore, et al. · Journal of Clinical Oncology
Viral vs non-viral combined hepatocellular–cholangiocarcinoma: Distinct genomic landscapes and survival outcomes.
2026 · Neha Puttagunta, Matthew Friedman, et al. · Journal of Clinical Oncology
PDF
Palliative care utilization in patients with EGFR -mutant metastatic non-small cell lung cancer receiving first-line EGFR TKIs.
2026 · Divya Chukkalore, Wint Yan Aung, et al. · Journal of Clinical Oncology
Clinicogenomic characterization of MUC16 and MUC17 in small cell lung cancer.
2026 · Nina Cheranda, Neha Puttagunta, et al. · Journal of Clinical Oncology
Infection rates and mortality in multiple myeloma: Impact of blood counts and IgG levels over time
2025 · Neha Puttagunta, Phyu Thin Naing, et al. · Blood
PDF
P2.06.10 Title: Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-Small Cell Lung Cancer: A cBioPortal Analysis
2025 · D. Chukkalore, W.Y. Aung, et al. · Journal of Thoracic Oncology
Works count: 16
Citation count: 18
H-index: 1
I10-index: 1
Year
Topic
Type